The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children
Related Experiment Video
Updated: Jul 19, 2026

Moderate Prenatal Alcohol Exposure and Quantification of Social Behavior in Adult Rats
Published on: December 14, 2014
Katriina Viinikainen1, Kai Eriksson, Anne Mönkkönen
1Kuopio Epilepsy Center, Department of Neurology, Kuopio University Hospital and University of Kuopio, POB 1777, 70211, Kuopio, Finland. hkviinik@hytti.uku.fi
Insights
Children exposed to valproate during pregnancy showed increased risks for neurological and behavioral issues, requiring more educational support compared to controls. Further research is needed to confirm these findings.
Area of Science:
- Neuroscience
- Developmental Pediatrics
- Clinical Neurology
Background:
- Prenatal exposure to antiepileptic drugs (AEDs) can impact child neurodevelopment.
- Valproate and carbamazepine are commonly used AEDs with potential teratogenic effects.
Purpose of the Study:
- To evaluate neurological functioning, behavior, and educational needs in children exposed prenatally to valproate monotherapy.
- To compare outcomes with age- and gender-matched controls exposed to carbamazepine and unexposed children.
Main Methods:
- Population-based cohort study identifying children exposed to valproate (N=13) from a pregnancy registry (1989-2000).
- Clinical neurological and neuropsychological assessments were performed.
- Behavioral problems were assessed using the Conners' Teacher Rating Scale (CTRS).
Main Results:
- Children exposed to valproate had significantly higher rates of requiring educational support (62%) compared to carbamazepine-exposed (15%) and nonexposed (15%) groups (P=0.022).
- Minor dysmorphic features were more common in the valproate-exposed group (62%).
- Valproate-exposed children exhibited more behavioral problems on the CTRS.
Conclusions:
- Prenatal valproate exposure was associated with a higher incidence of cognitive, neurological, and behavioral problems in children.
- These findings highlight potential neurodevelopmental risks associated with in utero valproate exposure.
- Larger prospective studies are recommended to validate these observations due to confounding factors.
Abstract:
Children exposed to valproate monotherapy in utero were evaluated with respect to neurological functioning, behavior, and additional educational needs, and the results were compared with those for age- and gender-matched controls exposed to carbamazepine and children with no prenatal exposure to antiepileptic drugs. We identified from the community-based pregnancy registry of Kuopio University Hospital area (1989-2000) all first-born and school-aged children exposed to valproate (N=13). Neurological and neuropsychological assessments were made clinically, and behavioral problems were assessed with the Conners' Teacher Rating Scale (CTRS). Eight children (62%) exposed to valproate and two (15%) each in the carbamazepine-exposed and nonexposed groups (P=0.022) required educational support. Minor dysmorphic features were noted in eight children (62%) exposed to valproate and in three children (23%) each in the carbamazepine-exposed and nonexposed groups. On CTRS, children exposed to valproate received higher scores, indicating behavioral problems. In our small but population-based study, all children exposed to valproate had minor, and some of them major, cognitive or neurological problems. This difference is clearly observed when assessing each child individually, but the many confounding factors explaining at least part of this difference are difficult to control and avoid in clinical practice. Larger studies with a prospective design are needed to confirm these findings.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Teratogenicity
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

